 After 1 year Week 56, participants who met eligibility criteria for the long-term extension phase NCT01070303 were switched to OL adalimumab 40 mg subcutaneous SC eow, and participants previously in the OL treatment group of Study NCT00055497 continued on their previous OL adalimumab dose adalimumab 40 mg SC eow or every week. 